#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	12734	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2499	618.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1670	1670	C	835	C,G	834,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	12734	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2499	618.0	0	HET	.	.	.	C260T	.	260	260	C	746	746	C	721	C,T	559,162	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20980	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4146	631.1	0	.	n	.	0	T695C	SNP	695	695	T	1307	1307	C	739	C	739	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20980	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4146	631.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1949	1949	A	840	A	840	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20980	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4146	631.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2583	2583	C	725	C,T	723,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20980	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4146	631.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3209	3209	T	724	T,G	721,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20980	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4146	631.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2657	2657	A	657	A	657	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2060	folP	852	852	100.0	folP.l15.c4.ctg.1	2110	121.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1268	1270	AGC	205;204;203	A,G;G;C	204,1;204;203	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4952	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3788	162.9	1	SNP	p	S91F	0	.	.	271	273	TCC	744	746	TCC	194;191;191	T,G;C;C	192,2;191;191	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4952	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3788	162.9	1	SNP	p	D95N	0	.	.	283	285	GAC	756	758	GAC	198;198;200	G,A;A;C	197,1;198;200	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4952	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3788	162.9	1	SNP	p	D95G	0	.	.	283	285	GAC	756	758	GAC	198;198;200	G,A;A;C	197,1;198;200	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	1988	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1944	127.5	1	SNP	p	G45D	1	.	.	133	135	GAC	781	783	GAC	204;203;199	G;A;C	204;203;199	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1040	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1679	77.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4634	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3443	167.7	1	SNP	p	D86N	0	.	.	256	258	GAC	881	883	GAC	230;229;227	G;A,C;C	230;227,2;227	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4634	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3443	167.7	1	SNP	p	S87W	0	.	.	259	261	AGT	884	886	AGT	227;231;231	A,T,G,C;G,A;T,C	224,1,1,1;230,1;230,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4634	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3443	167.7	1	SNP	p	S87I	0	.	.	259	261	AGT	884	886	AGT	227;231;231	A,T,G,C;G,A;T,C	224,1,1,1;230,1;230,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4634	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3443	167.7	1	SNP	p	S87R	0	.	.	259	261	AGT	884	886	AGT	227;231;231	A,T,G,C;G,A;T,C	224,1,1,1;230,1;230,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4634	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3443	167.7	1	SNP	p	S88P	0	.	.	262	264	TCC	887	889	TCC	230;229;233	T,C;C,T,G;C,G	229,1;226,2,1;232,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4144	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3086	166.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1844	1846	GGC	210;212;208	G;G;C	210;212;208	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	150.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1492	1494	GCA	223;229;228	G,A;C;A	222,1;229;228	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	150.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1495	1497	ATC	225;224;223	A;T,G;C	225;223,1;223	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	150.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1507	1509	GTG	222;224;222	G;T,A;G,C	222;222,2;221,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	150.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1507	1509	GTG	222;224;222	G;T,A;G,C	222;222,2;221,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	150.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2011	2013	ACC	193;195;198	A;C;C	193;195;198	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	150.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2065	2067	GCG	187;185;186	G;C;G	187;185;186	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	150.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2065	2067	GCG	187;185;186	G;C;G	187;185;186	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	150.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2188	2190	GGC	203;204;204	G;G,T;C	203;203,1;204	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	150.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2197	2199	GGC	198;198;198	G;G;C	198;198;198	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	150.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2215	2217	CCG	188;185;183	C,G;C;G,A,T	187,1;185;181,1,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	4902	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3774	162.1	1	SNP	p	L421P	0	.	.	1261	1263	CTG	2012	2014	CTG	202;203;201	C,A;T,G,A;G	201,1;201,1,1;201	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2550	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2207	143.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	710	710	C	201	C,A	200,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	306	porB1a	984	287	91.07	porB1a.l6.c30.ctg.2	1050	28.1	0	.	p	.	0	H217N	NONSYN	649	651	CAT	787	789	AAT	1;1;1	A;A;T	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	306	porB1a	984	287	91.07	porB1a.l6.c30.ctg.2	1050	28.1	0	.	p	.	0	D218N	NONSYN	652	654	GAT	790	792	AAT	1;1;1	A;A;T	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	306	porB1a	984	287	91.07	porB1a.l6.c30.ctg.2	1050	28.1	0	.	p	.	0	A222V	NONSYN	664	666	GCT	802	804	GTT	1;1;1	G;T;T	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	306	porB1a	984	287	91.07	porB1a.l6.c30.ctg.2	1050	28.1	0	.	p	.	0	V226A	NONSYN	676	678	GTA	814	816	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	306	porB1a	984	287	91.07	porB1a.l6.c30.ctg.2	1050	28.1	0	.	p	.	0	.	MULTIPLE	700	702	ACT	837	839	GTA	3;3;3	G;T;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	306	porB1a	984	287	91.07	porB1a.l6.c30.ctg.2	1050	28.1	0	.	p	.	0	D238fs	FSHIFT	712	712	G	849	849	G	4	G	4	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	G38E	NONSYN	112	114	GGA	476	478	GAA	222;222;224	G,C;A,G,C;A	221,1;220,1,1;224	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	S46G	NONSYN	136	138	AGC	500	502	GGC	217;217;221	G;G;C	217;217;221	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	E48G	NONSYN	142	144	GAA	506	508	GGA	226;226;224	G;G;A	226;226;224	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	T87A	NONSYN	259	261	ACT	623	625	GCT	213;211;212	G;C;T	213;211;212	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	T89S	NONSYN	265	267	ACC	629	631	AGC	204;204;203	A;G;C	204;204;203	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	.	MULTIPLE	358	359	AA	721	722	CG	182;183	C,A;G	181,1;183	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	.	MULTIPLE	361	362	GA	724	726	CAG	187;191;190	C,A;A,C;G	185,2;190,1;190	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	N122K	NONSYN	364	366	AAC	728	730	AAA	190;189;188	A;A;A	190;189;188	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	K143E	NONSYN	427	429	AAA	791	793	GAA	225;227;228	G;A;A	225;227;228	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	V151A	NONSYN	451	453	GTA	815	817	GCA	243;243;243	G,T;C;A	242,1;243;243	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1007	1009	ACT	231;231;229	A,C;C,A;T	229,2;230,1;229	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1016	1018	ATG	220;221;217	A;T;G	220;221;217	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1130	1132	GCA	192;191;190	G;C;A	192;191;190	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1133	1135	ACG	190;189;189	A;C;G	190;189;189	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	S258R	NONSYN	772	774	AGT	1136	1138	AGG	189;191;194	A,T;G,T;G	188,1;190,1;194	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1139	1141	GTT	194;196;195	G;T;T	194;196;195	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1199	1201	GTA	236;240;244	G;T,G;A	236;239,1;244	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1238	1240	ACT	249;253;253	A;C;T	249;253;253	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1244	1246	GAT	261;259;261	G;A;T	261;259;261	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1256	1258	CAC	288;292;292	C;A,C;C,T	288;291,1;291,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	1	SNP	p	G120K	1	.	.	358	360	AAG	721	723	CGG	182;183;184	C,A;G;G	181,1;183;184	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	1	SNP	p	D121N	0	.	.	361	363	GAC	724	727	CGC	187;190;193	C,A;G;C	185,2;190;193	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2660	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1549	204.9	1	SNP	p	A121D	1	.	.	361	363	GAC	724	727	CGC	187;190;193	C,A;G;C	185,2;190;193	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9270	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5336	216.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2276	2278	AAT	207;206;207	A;A,T;T	207;205,1;207	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1326	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1411	116.9	1	SNP	p	V57M	1	.	.	169	171	ATG	676	678	ATG	240;238;237	A;T;G	240;238;237	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
